SCHEMBL6538893

SCHEMBL6538893

Nc1nc(-c2ccccc2)c(-c2ccc(=O)n(CC(=O)N3CCCCC3)n2)cc1Cl

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.50
HTT P42858 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
TP53 P04637 2/20 0.49
USP2 O75604 1/20 0.49
ALOX15 P16050 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ALDH1A1 P00352 6/20 0.48
MAPT P10636 3/20 0.43
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
TSHR P16473 2/20 0.43
MAPK1 P28482 1/20 0.43
LMNA P02545 4/20 0.42
NPSR1 Q6W5P4 4/20 0.42
GBA1 P04062 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6538325 0.99 KDM4E (0.51) KDM4EHTTSMN1; SMN2TP53USP2
SCHEMBL6538751 0.91 TSHR (0.53) KDM4EHTTSMN1; SMN2TP53USP2
SCHEMBL6538342 0.91 SMN1; SMN2 (0.50) KDM4EHTTSMN1; SMN2TP53USP2
SCHEMBL6539046 0.87 TP53 (0.45) KDM4EHTTSMN1; SMN2TP53USP2
SCHEMBL6538899 0.85 TP53 (0.43) KDM4EHTTSMN1; SMN2TP53USP2
SCHEMBL6539022 0.84 TP53 (0.42) KDM4EHTTTP53ALDH1A1MAPT
SCHEMBL6538489 0.82 MEN1 (0.49) HTTSMN1; SMN2TP53ALDH1A1MAPT
SCHEMBL6538523 0.80 TP53 (0.42) HTTSMN1; SMN2TP53MAPTMEN1
SCHEMBL6539027 0.80 TP53 (0.49) KDM4EHTTSMN1; SMN2TP53USP2
SCHEMBL6538395 0.79 TP53 (0.52) KDM4EHTTSMN1; SMN2TP53HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof ADORA1, ADORA2A, P2RX5 KDM4E 3052/4885HTT 478/4885SMN1; SMN2 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.